Ocular complications of giant cell arteritis;Manifestations ophtalmologiques de la maladie de Horton

Revue de Medecine Interne

Volumn 34, Issue 7, 2013, Pages 421-430

  Liozon, E ^a   Ly, K H ^a   Robert, P Y ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Anterior ischemic optic neuropathy; Blindness; Central ciliary artery occlusion; Emergency; Giant cell arteritis

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FLUORESCEIN; GLUCOCORTICOID; HEMOGLOBIN; METHYLPREDNISOLONE; PREDNISONE;

ANTERIOR ISCHEMIC OPTIC NEUROPATHY; BLOOD CELL COUNT; BLURRED VISION; DIPLOPIA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; EARLY DIAGNOSIS; EMERGENCY CARE; ERYTHROCYTE SEDIMENTATION RATE; EYE PROTECTION; FLUORESCENCE ANGIOGRAPHY; GIANT CELL ARTERITIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAW CLAUDICATION; JAW DISEASE; OPHTHALMOSCOPY; PATIENT MONITORING; PREDICTION; RECURRENT DISEASE; RETINA ARTERY OCCLUSION; SHORT SURVEY; TRANSITIONAL BLINDNESS; TREATMENT DURATION; VISUAL IMPAIRMENT;

BLINDNESS; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; EMERGENCY MEDICAL SERVICES; EYE DISEASES; GIANT CELL ARTERITIS; HUMANS; ISCHEMIA; PHYSICIAN'S ROLE; RECURRENCE;

EID: 84879601250     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2013.02.030     Document Type: Short Survey

References (112)

1. Hayreh S.S. Ophthalmic features of giant cell arteritis. Bailleres Clin Rheumatol 1991, 5:431-459.
2. Aiello P.D., Trautmann J.C., McPhee T.J., Kunselman A.R., Hunder GG Visual prognosis in giant cell arteritis. Ophthalmology 1993, 100:550-555.
3. Wagener H.P., Hollenhorst R.W. The ocular lesions of temporal arteritis. Trans Am Ophthalmol Soc 55:249-269.
4. Hollenhorst R.W., Brown J.R., Wagener H.P., Shick R.M. Neurologic aspects of temporal arteritis. Neurology 1960, 10:490-498.
5. Whitfield A.G., Bateman M., Cooke W.T. Temporal arteritis. Br J Ophthalmol 1963, 47:555-566.
6. Liu G.T., Glaser J.S., Schatz N.J., Smith J.L. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994, 101:1779-1785.
7. Gonzalez-Gay M.A., Blanco R., Rodriguez-Valverde V., Martinez-Taboada V.M., Delgado-Rodriguez M., Figueroa M., et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998, 41:1497-1504.
8. Gonzalez-Gay M.A., Garcia-Porrua C., Llorca J., Hajeer A.H., Branas F., Dababneh A., et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161patients. Medicine 2000, 79:283-292.
9. Liozon E., Herrmann F., Ly K., Robert P.Y., Loustaud V., Soria P., et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174patients. Am J Med 2001, 111:211-217.
10. Font C., Cid M.C., Coll-Vinent B., Lopez-Soto A., Grau J.M. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 1997, 36:251-254.
11. Nesher G., Berkun Y., Mates M., Baras M., Nesher R., Rubinow A., et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004, 83:114-122.
12. Salvarani C., Cimino L., Macchioni P., Consonni D., Cantini F., Bajocchi G., et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005, 53:293-297.
13. Lee M.S., Smith S.D., Galor A., Hoffman G.S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006, 54:3306-3309.
14. Berger C.T., Wolbers M., Meyer P., Daikeler T., Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 2009, 48:258-261.
15. Caselli R.J., Hunder G.G., Whisnant J.P. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988, 38:352-359.
16. Hayreh S.S., Podhajsky P.A., Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998, 125:509-520.
17. Gonzalez-Gay M.A., Miranda-Filloy J.A., Lopez-Diaz M.J., Perez-Alvarez R., Gonzalez-Juanatey C., Sanchez-Andrade A., et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine 2007, 86:61-68.
18. Simons R.J., Cogan D.G. Occult temporal arteritis. Arch Ophthalmol 1962, 68:8-18.
19. Hayreh S.S., Podhajsky P.A., Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998, 125:521-526.
20. Graham E., Holland A., Avery A., Russell R.W. Prognosis in giant-cell arteritis. Br Med J 1981, 282:269-271.
21. Schmidt W.A., Krause A., Schicke B., Kuchenbecker J., Gromnica-Ihle E. Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis?. Rheumatology 2009, 48:383-385.
22. Foroozan R., Deramo V.A., Buono L.M., Jayamanne D.G., Sergott R.C., Danesh-Meyer H., et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003, 110:539-542.
23. Fastenberg D.M., Feldon S.E. Reversible choroidal vascular insufficiency without infarction in temporal arteritis. Graefes Arch Clin Exp Ophthalmol 1982, 218:327-330.
24. Hayreh S.S. Management of ischemic optic neuropathies. Indian J Ophthalmol 2011, 59:123-136.
25. Hayreh S.S. Anterior ischaemic optic neuropathy. differentiation of arteritic from non-arteritic type and its management. Eye 1990, 4:25-41.
26. Hayreh S.S. Ischemic optic neuropathy. Prog Retin Eye Res 2009, 28:34-62.
27. Danesh-Meyer H., Savino P.J., Gamble G.G. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005, 112:1098-1103.
28. Hayreh S.S., Zimmerman B., Kardon R.H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002, 80:355-367.
29. Chan C.C., Paine M., O'day J. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol 2005, 25:14-17.
30. Thomson G.T., Johnston J.L., Sharpe J.A., Inman R.D. Internuclear ophthalmoplegia in giant cell arteritis. J Rheumatol 1989, 16:693-695.
31. Johnston J.L., Thomson G.T., Sharpe J.A., Inman R.D. Internuclear ophthalmoplegia in giant cell arteritis. J Neurol Neurosurg Psychiatry 1992, 55:84-85.
32. Hughes T.A., Wiles C.M., Hourihan M. Cervical radiculopathy and bilateral internuclear ophthalmoplegia caused by temporal arteritis. J Neurol Neurosurg Psychiatry 1994, 57:764-765.
33. Smetana G.W., Shmerling R.H. Does this patient have temporal arteritis?. JAMA 2002, 287:92-101.
34. Bengtsson B.A., Malmvall B.E. Giant cell arteritis. Acta Med Scand Suppl 1982, 658:1-102.
35. Bloch J., Morell-Dubois S., Koch E., Launay D., Maillard-Lefebvre H., Buchdahl A.L., et al. Hallucinations visuelles et maladie de Horton: à propos du syndrome de Charles Bonnet. Rev Med Interne 2011, 32:e119-e121.
36. Sonnenblick M., Nesher R., Rozenman Y., Nesher G. Charles Bonnet syndrome in temporal arteritis. J Rheumatol 1995, 22:1596-1597.
37. Razavi M., Jones R.D., Manzel K., Fattal D., Rizzo M. Steroid-responsive Charles Bonnet syndrome in temporal arteritis. J Neuropsychiatry Clin Neurosci 2004, 16:505-508.
38. Chertok P., Leroux J.L., Le Marchand M., Aboukrat P., Alary J.C., Blotman F. Orbital pseudo-tumor in temporal arteritis revealed by computerized tomography. Clin Exp Rheumatol 1990, 8:587-589.
39. Lee A.G., Tang R.A., Feldon S.E., Pless M., Schiffman J.S., Rubin R.M., et al. Orbital presentations of giant cell arteritis. Graefes Arch Clin Exp Ophthalmol 2001, 239:509-513.
40. Chisholm I.H. Cortical blindness in cranial arteritis. Br J Ophthalmol 1975, 59:332-333.
41. Randhawa S., Van Stavern G.P. Giant cell arteritis presenting with hemianopic visual field loss. Can J Ophthalmol 2007, 42:486-487.
42. Currie J., Lessell S. Tonic pupil with giant cell arteritis. Br J Ophthalmol 1984, 68:135-138.
43. Foroozan R., Buono L.M., Savino P.J., Sergott R.C. Tonic pupils from giant cell arteritis. Br J Ophthalmol 2003, 87:510-512.
44. Prasad S., Baccon J., Galetta S.L. Mydriatic pupil in giant cell arteritis. J Neurol Sci 2009, 284:196-197.
45. Védrine L., Rigal-Sastourne J.C., Coutant G., Defuentes G., Desramé J., Béchade D., et al. Une ischémie du segment antérieur de l'œil. Rev Med Interne 2003, 24:621-622.
46. Schmidt D. Ocular ichemia syndrome: a malignant course of giant cell arteritis. Eur J Med Res 2005, 10:233-242.
47. Hamed L.M., Guy J.R., Moster M.L., Bosley T. Giant cell arteritis in the ocular ischemic syndrome. Am J Ophthalmol 1992, 113:702-705.
48. Hwang J.M., Girkin C.A., Perry J.D., Lai J.C., Miller N.R., Hellmann D.B. Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite corticosteroid treatment. Am J Ophthalmol 1999, 127:102-104.
49. Casson R.J., Fleming F.K., Shaikh A., James B. Bilateral ocular ischemic syndrome secondary to giant cell arteritis. Arch Ophthalmol 2001, 119:306-307.
50. Rajesh C.V., Cole M. Panuveitis as a presenting feature of giant cell arteritis. Br J Ophthalmol 2000, 84:340.
51. Hayreh S.S. Blood supply of the optic nerve head and its role in optic atrophy, glaucoma, and oedema of the optic disc. Br J Ophthalmol 1969, 53:721-748.
52. Henkind P., Charles N.C., Pearson J. Histopathology of ischemic optic neuropathy. Am J Ophthalmol 1970, 69:78-90.
53. Wilkinson I.M., Russell R.W. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 1972, 27:378-391.
54. Cullen J.F., Coleiro J.A. Ophthalmic complications of giant cell arteritis. Surv Ophthalmol 1976, 20:247-260.
55. Barricks M.E., Traviesa D.B., Glaser J.S., Levy I.S. Ophthalmoplegia in cranial arteritis. Brain 1977, 100:209-221.
56. Eliskova M. Blood vessels of the ciliary ganglion in man. Br J Ophthalmol 1973, 57:766-772.
57. Huna-Baron R., Mizrachi I.B., Glovinsky Y. Intraocular pressure is low in eyes with giant cell arteritis. J Neuroophthalmol 2006, 26:273-275.
58. Hayreh S.S. Anterior ischaemic optic neuropathy. II. Fundus on ophthalmoscopy and fluorescein angiography. Br J Ophthalmol 1974, 58:964-980.
59. Siatkowski R.M., Gass J.D., Glaser J.S., Smith J.L., Schatz N.J., Schiffman J. Fluoresceine angiography in the diagnosis of giant cell arteritis. Am J Ophthalmol 1993, 115:57-63.
60. Mack H.G., O'Day J., Currie J.N. Delayed choroidal perfusion in giant cell arteritis. J Clin Neuroophthalmol 1991, 11:221-227.
61. Slavin M.L., Barondes M.J. Visual loss caused by choroidal ischemia preceding anterior ischemic optic neuropathy in giant cell arteritis. Am J Ophthalmol 1994, 117:81-86.
62. Melberg N.S., Grand M.G., Dieckert J.P., Barney N.P., Blumenkranz M.S., Boone D.E., et al. Cotton-wool spots and the early diagnosis of giant cell arteritis. Ophthalmology 1995, 102:1611-1614.
63. Cohen S., Gardner F. Bilateral choroidal ischemia in giant cell arteritis. Arch Ophthalmol 2006, 124:922.
64. Liozon F. La maladie de Horton. Ann Med Interne 1989, 140:122-141.
65. Vinckier L., Hatron P.Y., Gadenne C., Catteau M.H., Gosset D., Devulder B. Intérêt du Doppler artériel dans la maladie de Horton. Étude prospective de 59observations. J Mal Vasc 1989, 14(Suppl. C):116-122.
66. Ho A.C., Sergott R.C., Regillo C.D., Savino P.J., Lieb W.E., Flaharty P.M., et al. Color Doppler hemodynamics of giant cell arteritis. Arch Ophthalmol 1994, 112:938-945.
67. Ghanchi F.D., Williamson T.H., Lim C.S., Butt Z., Baxter G.M., McKillop G., et al. Colour Doppler imaging in giant cell (temporal) arteritis: serial examination and comparison with non-arteritic anterior ischaemic optic neuropathy. Eye (Lond) 1996, 10(Pt 4):459-464.
68. Lee A.G., Eggenberger E.R., Kaufman D.I., Manrique C. Optic nerve enhancement on magnetic resonance imaging in arteritic ischemic optic neuropathy. J Neuroophthalmol 1999, 19:235-237.
69. Garcia-Porrua C., Santamarina R., Armesto V., Gonzalez-Gay M.A. Magnetic resonance imaging in optic neuritis due to giant cell arteritis. Arthritis Rheum 2005, 53:313-314.
70. Geiger J., Ness T., Uhl M., Lagrèze W.A., Vaith P., Langer M., et al. Involvement of the ophthalmic artery in giant cell arteritis visualized by 3T MRI. Rheumatology 2009, 48:537-541.
71. Costello F., Zimmerman M.B., Podhajsky P.A., Hayreh S.S. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol 2004, 14:245-257.
72. Mackie S.L., Dasgupta B., Hordon L., Gough A., Green M., Hollywood J., et al. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology 2011, 50:2014-2022.
73. Cid M.C., Font C., Oristrell J., de la Sierra A., Coll-Vinent B., Lopez-Soto A., et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998, 41:26-32.
74. Gonzalez-Gay M.A., Barros S., Lopez-Diaz M.J., Garcia-Porrua C., Sanchez-Andrade A., Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240patients. Medicine 2005, 84:269-276.
75. Gonzalez-Gay M.A., Lopez-Diaz M.J., Barros S., Garcia-Porrua C., Sanchez-Andrade A., Paz-Carreira J., et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240patients. Medicine 2005, 84:277-290.
76. Lopez-Diaz M.J., Llorca J., Gonzalez-Juanatey C., Pena-Sagredo J.L., Martin J., Gonzalez-Gay M.A. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum 2008, 38:116-123.
77. Liozon E., Loustaud-Ratti V., Ly K., Soria P., Vidal E., Boutros-Toni F., et al. Visual prognosis in extremely old patients with temporal (giant cell) arteritis. J Am Geriatr Soc 2003, 51:722-723.
78. Loddenkemper T., Sharma P., Katzan I., Plant G.T. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 2007, 78:1255-1259.
79. Kelkel E., Sarrot-Reynauld F., Dussud C., Pasquier D., Massot C. Le retard diagnostique dans la maladie de Horton. Analyse du délai diagnostique à partir d'une étude rétrospective de 130cas. Rev Med Interne 1991, 12:265-268.
80. Ezeonyeji A.N., Borg F.A., Dasgupta B. Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol 2011, 30:259-262.
81. Liozon E., Boutros-Toni F., Ly K., Loustaud-Ratti V., Soria P., Vidal E. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course. J Rheumatol 2003, 30:1272-1276.
82. Hernandez-Rodriguez J., Font C., Garcia-Martinez A., Espigol-Frigolé G., Sanmarti R., Canete J.D., et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100patients. Medicine 2007, 86:233-241.
83. Dany F., Adenis J.P., Liozon F., Chastang A., Christides C. RÔle du Doppler dans le diagnostic des complications ophtalmologiques de la maladie de Horton. J Mal Vasc 1989, 14(Suppl. C):109-115.
84. Duhaut P., Pinède L., Bornet H., Demolombe-Ragué S., Dumontet C., Ninet J., et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Ann Rheum Dis 1999, 58:335-341.
85. Kaiser M., Weyand C.M., Björnsson J., Goronzy J.J. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998, 41:623-633.
86. Makkuni D., Bharadwaj A., Wolfe K., Payne S., Hutchings A., Dasgupta B. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis?. Rheumatology 2008, 47:488-490.
87. Chatelain D., Duhaut P., Schmidt J., Loire R., Bosshard S., Guernou M., et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis 2009, 68:84-88.
88. Borg E.J., Haanen H.C., Seldenrijk C.A. Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup. Clin Rheumatol 2007, 26:529-532.
89. Rauzy O., Fort M., Nourhashemi F., Alric L., Juchet H., Ecoiffier M., et al. Relation between HLA DRB1alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 1998, 57:380-382.
90. Weyand C.M., Kaiser M., Yang H., Younge B., Goronzy J.J. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002, 46:457-466.
91. Nesher G., Berkun Y., Mates M., Baras M., Rubinow A., Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004, 50:1332-1337.
92. Narvaez J., Bernad B., Gomez-Vaquero C., Garcia-Gomez C., Roig-Vilaseca D., Juanola X., et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 2008, 26(Suppl. 49):S57-S62.
93. Martinez-Lado L., Calvino-Diaz C., Pineiro A., Dierssen T., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine 2011, 90:186-193.
94. Hayreh S.S., Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 2003, 217:239-259.
95. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. International Network for the Study of Systemic Vasculitides. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309-1318.
96. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Gomez-Acebo I., Pego-Reigosa R., Lopez-Diaz M.J., Vazquez-Trinanes M.C., et al. Strokes at time of disease diagnosis in a series of 287patients with biopsy-proven giant cell arteritis. Medicine 2009, 88:227-235.
97. Hayreh S.S. Steroid therapy for visual loss in patients with giant cell arteritis. Lancet 2000, 355:1572-1573.
98. Fraser J.A., Weyand C.M., Newman N.J., Biousse V. The treatment of giant cell arteritis. Rev Neurol Dis 2008, 5:140-152.
99. Agard C., Barrier J.H. La maladie de Horton compliquée: modalités thérapeutiques. Presse Med 2004, 33:51-59.
100. Rosenfeld S.I., Kosmorsky G.S., Klingele T.G., Burde R.M., Cohn E.M. Treatment of temporal arteritis with ocular involvement. Am J Med 1986, 80:143-145.
101. Matzkin D.C., Slamovits T.L., Sachs R., Burde R.M. Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant-cell arteritis. Ophthalmology 1992, 99:68-71.
102. Mazlumzadeh M., Hunder G.G., Easley K.A., Calamia K.T., Matteson E.L., Griffing W.L., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006, 54:3310-3318.
103. Kupersmith M.J., Langer R., Mitnick H., Spiera R., Spiera H., Richmond M., et al. Visual performance in giant cell arteritis (temporal arteritis) after 1year of therapy. Br J Ophthalmol 1999, 83:796-801.
104. Feldman-Billard S., Héron E. La tolérance systémique des corticoïdes en ophtalmologie, en fonction de la voie d'administration. J Fr Ophtalmol 2008, 31:1026-1036.
105. Cornblath W.T., Eggenberger E.R. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 1997, 104:854-858.
106. Schmidt D., Vaith P., Hetzel A. Prevention of serious ophthalmic and cerebral complications in temporal arteritis?. Clin Exp Rheumatol 2000, 18:S61-S63.
107. Hayreh S.S., Zimmerman B. Visual deterioration in giant cell arteritis while on high doses of corticosteroid therapy. Ophthalmology 2003, 110:1204-1215.
108. Arashvand K., Alexander W.L., Dasgupta B. Duration of treatment after eye involvement in giant cell arteritis. J Rheumatol 2007, 34:1945.
109. Liozon E., Gondran G., Ly K., Loustaud V., Vidal E. Duration of treatment after eye involvement in giant cell arteritis. J Rheumatol 2008, 35:1220-1222.
110. Spiera R.F., Spiera H. Therapy for giant cell arteritis: can we do better?. Arthritis Rheum 2006, 54:3071-3074.
111. Buono L.M., Foroozan R., de Virgiliis M., Savino P.J. Heparin therapy in giant cell arteritis. Br J Ophthalmol 2004, 88:298-301.
112. Galor A., Lee M.S. Slowly progressive vision loss in giant cell arteritis. Arch Ophthalmol 2006, 124:416-418.